Y MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial

Raab, Marc S.; Engelhardt, Monika; Blank, Antje; Goldschmidt, Hartmut; Agis, Hermine; Blau, Igor W.; Einsele, Hermann; Ferstl, Barbara; Schub, Natalie; Roellig, Christoph; Weisel, Katja; Winderlich, Mark; Griese, Janine; Haertle, Stefan; Weirather, Johannes; Jarutat, Tiantom; Peschel, Christian; Chatterjee, Manik

dc.contributor.author	Weisel, Katja
dc.date.accessioned	2020-09-21T11:51:44Z
dc.date.available	2020-09-21T11:51:44Z
dc.date.issued	2020
dc.identifier.issn	2352-3026
dc.identifier.uri	http://hdl.handle.net/10900/106971
dc.language.iso	en	en
dc.publisher	Elsevier Sci Ltd	de_DE
dc.relation.uri	http://dx.doi.org/10.1016/S2352-3026(19)30249-2
dc.subject.ddc	610	de_DE
dc.title	Y MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial	de_DE
dc.type	Article	de_DE
utue.quellen.id	20200715072417_00664
utue.publikation.seiten	E381-E394	de_DE
utue.personen.roh	Raab, Marc S.
utue.personen.roh	Engelhardt, Monika
utue.personen.roh	Blank, Antje
utue.personen.roh	Goldschmidt, Hartmut
utue.personen.roh	Agis, Hermine
utue.personen.roh	Blau, Igor W.
utue.personen.roh	Einsele, Hermann
utue.personen.roh	Ferstl, Barbara
utue.personen.roh	Schub, Natalie
utue.personen.roh	Roellig, Christoph
utue.personen.roh	Weisel, Katja
utue.personen.roh	Winderlich, Mark
utue.personen.roh	Griese, Janine
utue.personen.roh	Haertle, Stefan
utue.personen.roh	Weirather, Johannes
utue.personen.roh	Jarutat, Tiantom
utue.personen.roh	Peschel, Christian
utue.personen.roh	Chatterjee, Manik
dcterms.isPartOf.ZSTitelID	Lancet Haematology	de_DE
dcterms.isPartOf.ZS-Issue	5	de_DE
dcterms.isPartOf.ZS-Volume	7	de_DE
utue.fakultaet	04 Medizinische Fakultät